So just in time for our nation’s birthday, I’m happy to report some good news. When it comes to healthcare analysis, both Republicans and Democrats can agree on one thing: Drug Channels is the go-to source!
Each political party’s major drug pricing policy document draws prominently from our research and writing. See below for the patriotic details of this historic bipartisan validation.
Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage. I’m proud that your friendly neighborhood blogger can be a unifying force for our troubled nation.
TRUSTED ON THE RIGHT
In May, the U.S. Department of Health & Human Services (HHS) released American Patients First, a report billed as “The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.”
The full document contained the following chart adapted from a DCI economic report on pharmacies and pharmacy benefit managers:
[Click to Enlarge]
The report’s endnote 7 also links to our 2017 analysis of the 340B Drug Pricing Program. (FYI: click here for our 2018 update.)
TRUSTED ON THE LEFT
Last week, the Minority Staff of the U.S. Senate Committee on Finance released A Tangled Web: An Examination of the Drug Supply and Payment Chain. The report includes a forward from Senate Finance Committee Ranking Member Ron Wyden (D-OR).
The Democrats' report opens with the following chart, adapted from an August 2017 Drug Channels blog post:
[Click to Enlarge]
The second chart in the report shows the buy-and-bill system for provider-administered drugs in Medicare Part B. That chart is adapted from a Drug Channels Institute economic report on pharmaceutical wholesalers and specialty distributors. The full report also contains references to no fewer than 19 Drug Channels articles.
So happy 242nd birthday, America! Perhaps there is hope for this great nation after all.